Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial

Journal of Clinical Oncology

Volumn 23, Issue 22, 2005, Pages 5108-5116

  Smith, Ian E ^a   Dowsett, Mitch ^a   Ebbs, Stephen R ^a   Dixon, J Michael ^a   Skene, Anthony ^a   Blohmer, J U ^a   Ashley, Susan E ^a   Francis, Stephen ^a   Boeddinghaus, Irene ^a   Walsh, Geraldine ^a  

^a MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LETROZOLE; PLACEBO; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HOT FLUSH; HUMAN; LONG TERM CARE; LUNG EMBOLISM; MASTECTOMY; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TREATMENT RESPONSE; ULTRASOUND; VAGINA DISCHARGE; BREAST TUMOR; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RISK; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; ODDS RATIO; PLACEBOS; POSTMENOPAUSE; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 24644490871     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.005     Document Type: Article

References (17)

1. Dixon JM, Anderson TJ, Miller WR: Neoadjuvant endocrine therapy of breast cancer: A surgical perspective. Eur J Cancer 38:2214-2221, 2002
2. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast carcinoma in postmenopausal women: Results of a North American multicenter randomized trial. J Clin Oncol 18:3758-3767, 2000
3. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001
4. Bonneterre J, Thurlimann B, Robertson JFR, et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748-3757, 2000
5. Dixon JM, Renshaw L, Bellamy C, et al: The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: A randomized, double-blind, single-center study. Clin Cancer Res 6:2229-2235, 2000
6. Miller WR, Dixon JM: Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 9:9-15, 2002
7. Dixon JM, Jackson J, Renshaw L, et al: Neoadjuvant tamoxifen and aromatase inhibitors: Comparisons and clinical outcomes. J Steroid Biochem Mol Biol 86:295-299, 2003
8. Milla-Santos A, Milla L, Rallo L, et al: Anastrozole as neoadjuvant therapy for hormone-dependent locally advanced breast cancer in postmenopausal patients. Proc Am Soc Clin Oncol 21:40a, 2002 (abstr 156)
9. Harper-Wynne CL, Sacks NPM, Shenton K, et al: Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 20:1026-1035, 2002
10. Eiermann W, Paepke S, Appfelstaedt J, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicentre study. Ann Oncol 12:1527-1532, 2001
11. Anderson TJ, Dixon JM, Stuart M, et al: Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large inoperable breast cancer. Br J Cancer 87:334-338, 2002
12. Arimidex Tamoxifen Alone or in Combination Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
13. WHO: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, WHO, WHO Offset Publication 48, 1979
14. Gaskell DJ, Hawkins RA, de Carteret S, et al: Indications for primary tamoxifen therapy in elderly women with breast cancer. Br J Surg 79:1317-1320, 1992
15. Newby JC, A'Hern RT, Leek RD, et al: Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: Validation against ligand binding assay and clinical relevance to breast cancer. Br J Cancer 71:1237-1242, 1995
16. Arimidex Tamoxifen Alone or in Combination Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: Results of the ATAC trial efficacy and safety update analyses. Cancer 98:1802-1810, 2003
17. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB1- and/or ErbB2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001